rform * "AVA-101 back to drawing board," next key catalyst may be decision on therapy in 1H after preclinical studies completed, Jefferies analyst Biren Amin writes; may also deprioritize its experimenta color blindness programs * PT to $20 vs $51, remains buy * AAVL 3 buys, 2 holds, 1 sell; avg PT $19.